Advertisement
Canada markets close in 2 hours 2 minutes
  • S&P/TSX

    22,368.51
    +109.35 (+0.49%)
     
  • S&P 500

    5,206.06
    +18.39 (+0.35%)
     
  • DOW

    39,307.63
    +251.24 (+0.64%)
     
  • CAD/USD

    0.7307
    +0.0019 (+0.26%)
     
  • CRUDE OIL

    79.04
    +0.05 (+0.06%)
     
  • Bitcoin CAD

    85,001.86
    -596.59 (-0.70%)
     
  • CMC Crypto 200

    1,335.81
    +35.71 (+2.75%)
     
  • GOLD FUTURES

    2,340.30
    +18.00 (+0.78%)
     
  • RUSSELL 2000

    2,066.50
    +11.37 (+0.55%)
     
  • 10-Yr Bond

    4.4610
    -0.0310 (-0.69%)
     
  • NASDAQ

    16,339.01
    +36.25 (+0.22%)
     
  • VOLATILITY

    13.00
    0.00 (0.00%)
     
  • FTSE

    8,381.35
    +27.30 (+0.33%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6777
    +0.0001 (+0.01%)
     

How AbbVie Could Hammer Gilead's Hepatitis C Franchise

How AbbVie Could Hammer Gilead's Hepatitis C Franchise

AbbVie is likely to swipe significant hepatitis C drug share from Gilead Sciences with an eight-week regimen, an analyst said Wednesday.